doi:10.1073/pnas.89.1.251
With the approval of the first oral GLP-1 and the potential for new indications, such as the treatment of Alzheimers disease, sleep apnea and certain types of cancers, the weight loss medication landscape will continue to move fast
On their own, GLP-1s produced modest gains: small improvements in sperm concentration, stable testosterone levels, and limited changes in total motile sperm count
doi: 10.3390/antiox12020470
Individual metabolic response, adherence, and lifestyle factors play a larger role in real-world outcomes than trial averages suggest
The key difference between Nevolat and other GLP-1 injections, like Wegovy and Mounjaro, is that it is taken daily rather than weekly